Lux Biosciences Completes Enrollment in Phase 3 Study of Non-infectious Uveitis Drug Candidate Luveniq

Lux Biosciences Completes Enrollment in Phase 3 Study of Non-infectious Uveitis Drug Candidate Luveniq

JERSEY CITY, N.J., Jul 09, 2012  -- Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq(TM) (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

The Phase 3 study is a six-month, randomized, multi-center, double-masked, controlled trial to evaluate the efficacy and safety of Luveniq for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye. The study includes 155 patients and is taking place at 56 sites across North America, Europe and Brazil. The primary endpoint of the trial is the change from baseline in vitreous haze at 12 weeks or at the time of treatment failure, if earlier.

Lux Biosciences anticipates that the results from this trial, if positive, will address the U.S. Food and Drug Administration's (FDA) request for additional clinical information as part of the Complete Response letter regarding the New Drug Application (NDA) for Luveniq issued in August 2010, and will support a resubmission of the NDA under priority review early in 2013. Lux Biosciences additionally expects the trial results, if positive, to support a regulatory filing to the European Medicines Agency for Luveniq.

Dean Mitchell, President and Chief Executive Officer of Lux Biosciences, commented, "The design of the current trial will allow us to build on the insights gained from the previously successful trial, while enhancing the understanding of how physicians may best use Luveniq in their patient population. We are very pleased with the conduct of the trial and thank the investigators involved for their tireless efforts and support in advancing this innovative and important therapy."


Luveniq is the oral form of a of a novel therapeutic agent, voclosporin. Luveniq reversibly inhibits immunocompetent lymphocytes, particularly T-lymphocytes, and it also inhibits lymphokine production and release. Lux Biosciences has exclusive worldwide rights to voclosporin for ophthalmic use and is cooperating with the team at Isotechnika Pharma who discovered the molecule and is developing it in solid organ transplantation.

About Uveitis

Uveitis, which represents a group of serious inflammatory eye conditions, is inevitably associated with either severe vision loss or substantial morbidity from steroid use. Non-infectious uveitis involving the posterior segment of the eye is a leading cause of vision loss and long-term disability and the fourth leading cause of legal blindness in the industrialized world. As the majority of uveitis patients are first diagnosed under 40 years of age, the socio-economic burden of this disease is higher than that of other serious ocular conditions such as AMD and diabetic macular edema.

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases with a high unmet medical need. For more information on Lux Biosciences, please visit the company's website at .

Lux Biosciences cautionary statement regarding forward-looking statements

This press release is not made on behalf of, or with authorization by, any other company or issuer of securities. To the extent that this press release may refer to any other issuer of securities, Lux Biosciences, Inc. makes no statement and expresses no recommendation or other opinion about any transaction or potential transaction concerning such securities.

This press release may contain forward-looking statements, including Lux Bioscience's belief as to the medical and commercial potential of its product candidates, Lux Bioscience's plans to pursue business and regulatory strategy, and Lux Bioscience's expectations regarding actions and decisions solely within the control and purview of other parties. These forward-looking statements involve important known and unknown risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the exercise of discretion by regulatory agencies and other parties, the availability to Lux Biosciences of funds and resources to pursue research and development projects, the performance of activities and generation of scientific data by parties other than Lux Biosciences, the ability of Lux Biosciences to economically manufacture and commercialize its products once approved, acceptance by the medical community of Lux Biosciences' products once approved and the availability of alternative therapeutic agents, approval for reimbursement by third-party payors of Lux Biosciences' products once approved, the success and timely completion of clinical trials and other scientific studies, the ability of Lux Biosciences and its licensors to defend its and their patents from infringement by third parties, and the risk that such patents may be subsequently shown to be invalid or that the practice of such patents may infringe the patents of others. Further, Lux Biosciences disclaims any undertaking to issue further press releases or otherwise advice about changes to these beliefs, plans and expectations.

SOURCE: Lux Biosciences, Inc.